MAM
LFCR icon

Meeder Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Meeder Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,873
Closed -$10.7K – 999
2026
Q1 		$10.7K Buy
+2,873
New +$19.8K ﹤0.01% 682

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Meeder Asset Management's LFCR Position: Q2 2026 in Review

Meeder Asset Management sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 2,873 shares — an estimated $10.7K sold.

Meeder Asset Management first reported a position in LFCR in Q1 2026 and held it in 1 quarter. The position peaked at $10.7K in Q1 2026. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Meeder Asset Management reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 2,873 Lifecore Biomedical shares in Q2 2026, an estimated $10.7K.
  • Meeder Asset Management first reported a position in Lifecore Biomedical in Q1 2026 and held it in 1 quarter.
  • Meeder Asset Management's Lifecore Biomedical position peaked at $10.7K in Q1 2026.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.